Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Avadel Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.46|
|52 Week High||US$4.95|
|52 Week Low||US$10.80|
|1 Month Change||6.42%|
|3 Month Change||16.05%|
|1 Year Change||63.64%|
|3 Year Change||104.84%|
|5 Year Change||-26.94%|
|Change since IPO||-28.00%|
Recent News & Updates
Avadel Pharmaceuticals, The Jazz-Killer
Avadel's once-nightly FT218 improves considerably over Xyrem's twice-nightly dosing. Jazz's recent lawsuit seems spurious, given how they lost to Amneal before. October PDUFA and current low prices make AVDL a compelling buy.
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Avadel Pharmaceuticals ([[AVDL]]) announces new post hoc analyses of data from Phase 3 REST-ON trial of FT218. FT218 is currently under FDA review with PDUFA target date of October 15, 2021. Highlights from the poster presentations are outlined below. Efficacy of FT218 by Narcolepsy Subtype:FT218 demonstrated statistically significant improvement in excessive daytime sleepiness ((EDS)) at all evaluated doses in patients with narcolepsy subtypes 1 (NT1, with cataplexy) and 2 (NT2, without cataplexy) compared to placebo.The least squares ((LS)) mean difference in
|AVDL||US Pharmaceuticals||US Market|
Return vs Industry: AVDL exceeded the US Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: AVDL exceeded the US Market which returned 30% over the past year.
Stable Share Price: AVDL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AVDL's weekly volatility (9%) has been stable over the past year.
About the Company
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company’s lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017.
Avadel Pharmaceuticals Fundamentals Summary
|AVDL fundamental statistics|
Is AVDL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVDL income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.96|
|Net Profit Margin||0.00%|
How did AVDL perform over the long term?See historical performance and comparison
Is Avadel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVDL ($8.46) is trading below our estimate of fair value ($122.2)
Significantly Below Fair Value: AVDL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AVDL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: AVDL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVDL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVDL is overvalued based on its PB Ratio (4.2x) compared to the US Pharmaceuticals industry average (3.1x).
How is Avadel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVDL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AVDL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AVDL's is expected to become profitable in the next 3 years.
Revenue vs Market: AVDL's revenue (60.3% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: AVDL's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVDL's Return on Equity is forecast to be high in 3 years time
How has Avadel Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVDL is currently unprofitable.
Growing Profit Margin: AVDL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVDL is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.
Accelerating Growth: Unable to compare AVDL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: AVDL has a negative Return on Equity (-47.11%), as it is currently unprofitable.
How is Avadel Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AVDL's short term assets ($230.7M) exceed its short term liabilities ($16.3M).
Long Term Liabilities: AVDL's short term assets ($230.7M) exceed its long term liabilities ($147.4M).
Debt to Equity History and Analysis
Debt Level: AVDL's debt to equity ratio (119.3%) is considered high.
Reducing Debt: AVDL's debt to equity ratio has increased from 1.5% to 119.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVDL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AVDL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Avadel Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVDL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVDL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVDL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVDL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVDL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Greg Divis (54 yo)
Mr. Gregory J. Divis Jr., also known as Greg, has been the Chief Executive Officer and Director of Avadel Pharmaceuticals plc since June 3, 2019. Mr. Divis served as an Interim Chief Executive Officer at A...
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD3.14M) is above average for companies of similar size in the US market ($USD1.70M).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
Experienced Management: AVDL's management team is considered experienced (2.5 years average tenure).
Experienced Board: AVDL's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Avadel Pharmaceuticals plc's employee growth, exchange listings and data sources
- Name: Avadel Pharmaceuticals plc
- Ticker: AVDL
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$495.724m
- Shares outstanding: 58.60m
- Website: https://www.avadel.com
Number of Employees
- Avadel Pharmaceuticals plc
- 10 Earlsfort Terrace
- Co. Dublin
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 23:33|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.